Stock Events

Sensorion 

€0.79
0
+€0+0% Today

Statistics

Day High
0.8
Day Low
0.79
52W High
-
52W Low
-
Volume
0
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

13MarExpected
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q3 2023
Next
-0.18
-0.12
-0.06
0
Expected EPS
-0.15
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RFM.F. It's not an investment recommendation.

About

Sensorion SA, a clinical-stage biopharmaceutical company, develops therapies for the treatment of inner ear disorders in France. It engages in developing USHER-GT, a gene therapy development program to restore inner ear function for patients suffering from usher syndrome Type 1; OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. The company's pipeline includes various products in development stage for restoring, treating, and preventing inner ear related disorders. Sensorion SA has a collaboration agreement with Institut Pasteur for gene therapy program to restore auditory functions; and a strategic collaboration with Sonova Holding AG to introduce genetic analysis for routine diagnosis of progressive hearing loss in adults through a combination of advanced therapeutic interventions and traditional hearing aids. The company was founded in 2009 and is headquartered in Montpellier, France.
Show more...
CEO
Employees
34
Country
DE
ISIN
FR0012596468
WKN
000A14SVV

Listings